NCT05485792: FAPI-VTC

18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer

Status unknown NA Last updated 3 August 2022

What this trial tests

NA trial testing 18F-FAPI PET/CT and 18F-FDG PET/CT in Cancer in 200 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
30 December 2022

30 December 2023

Quick facts

Lead sponsor	Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	200
Start date	1 August 2022
Primary completion	30 December 2022
Estimated completion	30 December 2023

Drugs / interventions tested

• 18F-FAPI PET/CT and 18F-FDG PET/CT

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Who can join

Adults 18 to 90, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

FAP is overexpressed in the cancer-associated fibroblasts (CAFs) of 90% epithelial carcinomas. Currently, 68Ga-fibroblast activation protein inhibitor (FAPI) has shown promising diagnostic value in many types of tumors. However, there are currently no studies on head-to-head comparison of diagnosis value of various types of cancer in 18F-FAPI and 18F-FDG PET/CT. Therefore, we conducted a prospective study to investigate the value of 18F-FAPI PET/CT in various types of cancer, and compare it with 18F-FDG PET/CT.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
   Pei L, Liu Y, Liu L, Gao S, et al · · 2023 · cited 170× · PMID 36759842 · DOI 10.1186/s12943-023-01731-z
2. Head-to-head comparison of ¹⁸F-FAPI and ¹⁸F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma.
   Zhang J, Jiang S, Li M, Xue H, et al · · 2023 · cited 34× · PMID 37899452 · DOI 10.1186/s40644-023-00626-y
3. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.
   Zhang Z, Tao J, Qiu J, Cao Z, et al · · 2024 · cited 21× · PMID 37726505 · DOI 10.1007/s13402-023-00872-z
4. Head-to-head study of [<sup>18</sup>F]FAPI-04 PET/CT and [<sup>18</sup>F]FDG PET/CT for non-invasive assessment of liver cancer and its immunohistochemical markers.
   Liang Z, Peng H, Li W, Liu Z. · · 2024 · cited 8× · PMID 39528951 · DOI 10.1186/s12885-024-13153-1
5. Role of [¹⁸F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: prospective comparison with [¹⁸F]FDG PET/CT.
   Liang J, Jiang S, Song J, Chen D, et al · · 2024 · cited 6× · PMID 39256297 · DOI 10.1186/s13550-024-01145-y
6. Cancer-Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy.
   Fan C, Zhu W, Chen Y, Zhu W, et al · · 2025 · cited 4× · PMID 41164803 · DOI 10.1002/mco2.70415
7. Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities.
   Wang M, Zhao Y, Xu K, Liu C, et al · · 2025 · cited 4× · PMID 40534854 · DOI 10.3389/fimmu.2025.1617968
8. Diagnostic performance of [<sup>18</sup>F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI.
   Liang J, Weng S, Zhang J, Jiang S, et al · · 2025 · cited 2× · PMID 40232335 · DOI 10.1007/s00259-025-07273-4